Overview

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.
Phase:
Phase 3
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Arizona State University
The Biodesign Institute
Treatments:
Carboplatin